bioAffinity Technologies, Inc. — Cyborg Score 4/10
Mixed
Biotechnology/Diagnostics - Oncology
Strategic Profile
The company operates through two segments: Diagnostic Research and Development and Laboratory Services, offering CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum to find characteristics indicative of lung cancer. CyPath® Lung orders grew by approximately 1,400% over full-year 2023, and the test received Medicare and private insurance reimbursement following CMS addition of a unique CPT code effective January 1, 2024.
Cyborg Score Rationale
CyPath® Lung testing revenue achieved an 86% increase in Q3 2025 demonstrating strong commercial traction and market adoption. However, capital constraints remain a concern with analysts maintaining a Hold rating due to the company's inability to operate profitably and the need to raise additional capital. The company faces typical pre-profitability biotech challenges despite impressive revenue growth.
Top Insights
CyPath® Lung orders grew by approximately 1,400% over full-year 2023, reflecting rapid market adoption.
CyPath® Lung received Medicare and private insurance reimbursement through CMS 2024 clinical laboratory schedule effective January 1, dramatically expanding addressable market.
Company is developing diagnostic tests for Chronic Obstructive Pulmonary Disease (COPD) and asthma, building on expertise in sputum-based flow cytometric analysis.
Cash position declined from $2.8 million to $1.1 million between end of 2023 and end of 2024, presenting near-term funding requirements.
Named Competitors
Biodesix — Lung cancer molecular diagnostics and companion diagnostics
Early-stage cancer detection platforms — Other liquid biopsy and non-invasive diagnostic platforms in development
Recent Developments
(February 2026) Appointed nationally recognized pulmonary and lung cancer authorities to Medical and Scientific Advisory Board
(January 2026) Laboratory maintained prestigious College of American Pathologists (CAP) accreditation
(Q3 2025) Achieved 86% increase in CyPath® Lung testing revenue